Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-25, FY ended December 31, 2025) + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP — Unqualified opinion
One-line verdict: Altria is a $20.1B revenue tobacco company generating extraordinary cash flow — CFFO/NI of 1.34 and $9.1B in free cash flow on $6.95B net income — from a secular declining business. Smokeable products revenue fell 3.4% as cigarette volumes continue their structural decline. The e-vapor strategy through NJOY has collapsed: a U.S. International Trade Commission exclusion order banned NJOY ACE imports effective March 2025, triggering $873M in goodwill impairment and $978M in definite-lived intangible asset impairment in the e-vapor reporting unit — over $1.85B in write-downs from a $2.75B acquisition. The M-Score of -2.36 passes but sits closest to the manipulation threshold in this cohort. Cash of $4.5B covers only 17% of $25.7B in total debt (including Master Settlement Agreement obligations), AR outpaced revenue for two years, CapEx surged 52%, and write-offs jumped 151%. The cash machine works, but every strategic bet beyond cigarettes has destroyed value.
| Metric | Result |
|---|---|
| Red Flags | **2** (AR outpacing revenue 2 years, cash covers 17% of debt) |
| Watch Items | **2** (CapEx +52.1% vs revenue -1.5%, write-offs +151%) |
| Checks Completed | **18/18** |
| Beneish M-Score | **-2.36** (narrowly clean; threshold is -2.22) |
| Altman Z-Score | **4.63** (safe zone) |
| Auditor | PricewaterhouseCoopers LLP — Unqualified opinion |
The Business: Cigarettes, Oral Tobacco, and a Failed E-Vapor Bet
Altria's segments tell the story of a company in transition. Smokeable products ($20.5B revenue, $11.0B OCI) dominate — Marlboro holds roughly 42% U.S. cigarette market share. Oral tobacco products ($2.8B revenue, $1.8B OCI) include on! nicotine pouches and Copenhagen/Skoal MST brands. E-vapor ($-13M revenue, $-2.3B OCI) is a catastrophe — the NJOY ACE import ban rendered the $2.75B NJOY acquisition nearly worthless.
Per the filing, settlement charges of $3.0B were recorded in smokeable products OCI — payments under the Master Settlement Agreement with 46 states. Excise taxes consumed another $3.0B.
Profitability: Decline Masked by Buybacks
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Net Revenue (excl. excise) | $20.7B | $20.5B | $20.4B | $20.1B | -3% over 4 years |
| Net Income | $5.76B | $8.13B | $11.26B | $6.95B | Volatile; FY2024 included $2.7B IQOS gain |
| Gross Margin | 68.9% | 69.7% | 70.3% | 72.2% | Expanding +1.9pp |
| Operating Income | — | $11,547M | $11,241M | $9,899M | -12% YoY |
FY2024 net income of $11.26B was inflated by the $2.7B gain on sale of IQOS System commercialization rights to Philip Morris International. Adjusting for this, normalized earnings were approximately $8.5B. FY2025's $6.95B was depressed by the $1.85B in NJOY impairments and $978M in definite-lived intangible impairments.
The 72.2% gross margin is exceptional — tobacco remains one of the highest-margin consumer products businesses in existence.
Cash Flow: The Cash Machine
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $9.29B | $8.76B | $9.32B |
| Net Income | $8.13B | $11.26B | $6.95B |
| **CFFO / Net Income** | **1.14** | **0.78** | **1.34** |
| CapEx | $0.20B | $0.16B | $0.24B |
| Free Cash Flow | $9.09B | $8.61B | $9.07B |
| **FCF / Net Income** | **1.12** | **0.76** | **1.31** |
Free cash flow of $9.1B on a $20.1B revenue base is extraordinary — 45% FCF margin. CapEx requirements of just $240M reflect the asset-light nature of cigarette manufacturing. The CFFO/NI ratio of 0.78 in FY2024 was depressed by the $2.7B IQOS gain (non-cash). Normalizing for one-time items, the cash conversion engine is consistent and powerful.
Per the filing, Altria's Consolidated EBITDA was $12.6B, and the Debt/Consolidated EBITDA ratio was 2.0x — well within covenant requirements under its $3.0B Credit Agreement.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | PASS | DSO 5 days, +2 days YoY |
| A2 | AR vs Revenue Growth | FAIL | AR outpaced revenue for 2 consecutive years |
| A3 | Revenue vs CFFO | PASS | Revenue -1.5%, CFFO +6.1% |
A2 — AR divergence in a declining revenue business. When a company's revenue is declining but receivables are growing, it may indicate extended payment terms or channel loading. In tobacco, where the regulatory environment restricts marketing, revenue manipulation tools are limited. But the two-year divergence merits flagging.
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | PASS | Inventory -0.9% vs COGS -7.9%. Normal |
| B2 | CapEx vs Revenue | WATCH | CapEx +52.1% vs revenue -1.5% |
| B3 | SG&A Ratio | PASS | SG&A/Gross Profit = 17.2%. Excellent |
| B4 | Gross Margin | PASS | 72.2%, +1.9pp. Expanding |
B2 — CapEx surge from $158M to $240M reflects investment in NJOY and other smoke-free product manufacturing despite the ITC ban. The absolute spending level remains modest relative to the business.
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | PASS | CFFO/NI = 1.34. Strong |
| C2 | Free Cash Flow | PASS | FCF $9.1B, FCF/NI = 1.31 |
| C3 | Accruals Ratio | PASS | -6.7%. Low accruals |
| C4 | Cash vs Debt | FAIL | Cash $4.5B covers only 17% of debt $25.7B |
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | PASS | $17.7B = -504% of equity. Manageable (negative equity distorts ratio) |
| D2 | Leverage | PASS | Debt/EBITDA = 2.4x. Healthy |
| D3 | Soft Asset Growth | PASS | Other assets +17.2% vs revenue -1.5%. Normal |
| D4 | Asset Impairment | WATCH | Write-offs up 151% YoY |
D4 — Massive impairments. The e-vapor reporting unit recorded $873M in goodwill impairment and $978M in definite-lived intangible impairment in FY2025. Per the filing: "This impairment was due primarily to (i) lower projected volume and revenue due to NJOY ACE's removal from the U.S. market and (ii) higher projected costs associated with the commercialization of NJOY's future e-vapor product portfolio." After the goodwill impairment, the e-vapor unit's carrying value of goodwill was $895M. Remaining definite-lived intangible assets were further written down in Q4 after Altria concluded "effective enforcement against illicit flavored disposable e-vapor products would likely occur gradually over a longer period of time."
Note: D1 passes because Altria has negative total equity ($-3.5B) due to decades of share buybacks. The goodwill/equity ratio is technically negative and thus not flagged by the screen, but $17.7B in goodwill/intangibles is enormous on an absolute basis.
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | PASS | FCF after acquisitions positive |
| E2 | Goodwill Surge | PASS | Goodwill+Intangibles -11% YoY (due to impairments) |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | PASS | -2.36 (threshold: < -2.22) |
The M-Score of -2.36 is the narrowest pass in this cohort, just 0.14 points below the manipulation threshold. The combination of declining revenue, expanding gross margins, and growing AR creates a profile that warrants close monitoring.
Key Risks from the 10-K
1. NJOY — $1.85B Impairment and ITC Ban
The ITC exclusion order and cease-and-desist orders prohibiting NJOY ACE importation and sale became effective March 31, 2025. Altria's $2.75B NJOY acquisition has been substantially written down. The filing discloses: "We may not be able to realize the expected benefits of our acquisition of NJOY Holdings, Inc. in the expected manner or timeframe, if at all."
2. Secular Volume Decline in Cigarettes
Smokeable products revenue declined 3.4% as volumes continue structural decline. The Master Settlement Agreement requires annual payments of approximately $3.0B. As volumes decline, the per-pack cost of these payments increases, creating a flywheel of price increases that accelerate further volume decline.
3. Illicit E-Vapor Market Competition
"Illicit disposable e-vapor and oral nicotine pouch products may be designed to appeal to youth and are manufactured without scientific standards." The filing extensively discusses the damage from illicit products to legal competitors like NJOY, estimating that effective enforcement "would likely occur gradually over a longer period of time."
4. Serial Value Destruction in Diversification
Altria's track record of investments beyond cigarettes is catastrophic: JUUL ($12.8B investment, divested in March 2023 for near-total loss), Cronos Group (cannabis investment, not yet returned expected value), and now NJOY ($2.75B acquisition, $1.85B impaired in year one). Each was supposed to be the answer to cigarette decline; each has destroyed capital.
5. Supplier Finance and Guarantor Structure
PM USA guarantees Altria's debt obligations. ALCS supplier financing program is guaranteed by Altria. The filing discloses total debt/Consolidated EBITDA of 2.0x and the credit agreement includes financial covenants.
Summary
Grade: F. Two quantitative fails plus two watch items on a company that generates $9.1B in free cash flow but has systematically destroyed value in every strategic bet beyond cigarettes.
Altria is a paradox: the most cash-generative business model in consumer staples (45% FCF margin, 72.2% gross margin) housed inside a declining industry with $25.7B in debt and a trail of failed diversification investments totaling over $15B in value destruction (JUUL, NJOY, Cronos). The NJOY impairment of $1.85B in FY2025 is the latest chapter. The M-Score of -2.36 narrowly passes.
The cash machine is real and enormous. But every dollar generated beyond dividend obligations ($6.9B annually) has been allocated to investments that have not worked. The F grade reflects the structural leverage, the AR quality flag, and the ongoing impairment risk — not the operating quality of the cigarette business, which remains excellent.
**Disclaimer**: This report is based on Altria Group's FY2025 10-K filed with SEC EDGAR on February 25, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP (Unqualified opinion)
Fiscal year ended: December 31, 2025